jadomycin b

Jadomycin B is a natural product and angucycline antibiotic produced by fermentation of Streptomyces venezuelae. It features an unusual 8H-benz[b]oxazolo[3,2-f]-phenanthridine ring system and is glycosylated with the rare sugar L-digitoxose[4][5]. Jadomycin B exhibits potent cytotoxic activity against both drug-sensitive and multidrug-resistant breast cancer cells, including triple-negative breast cancer models[1][2][3]. Its mechanisms include inhibition of type II topoisomerases leading to DNA damage and apoptosis, as well as inhibition of Aurora-B kinase via reduced phosphorylation of histone H3 on Ser10[4]. Jadomycin B also displays antimicrobial activity against various staphylococci (including methicillin-resistant Staphylococcus aureus)[4], acts as a DNA-cleaving agent in the presence of copper ions by generating hydroxyl radicals, and has been shown to act synergistically with NSAIDs in preclinical studies[1][7]. Preclinical animal studies indicate partial anti-tumoral effects with good safety profiles; it does not appear directly toxic to T cells but may reduce T cell activation frequency[3].

Other names

149633-99-8(3aS)-jadomycin BCHEMBL1631684CHEMBL-1631684CHEMBL 1631684